Gland Pharma Limited
NSE: GLANDPharmaceuticals
Share price
₹3,079.10
-2.27% close of 8 Oct 2026
Business score
How strong the business is, in one number. The parts behind it are in Pro.
67
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹49,266 Cr
P/E ratio
43.0
P/B ratio
4.9
ROCE
15.1%
ROE
10.7%
Dividend yield
0.6%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Sales grew 17.6% over the past year, and 13.4% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales slipped from 32.7% to 25.8% over the last four years.
Whether it grew faster than its sector
It grew 13.4% a year against a sector median of 13.1% — 0.3 percentage points faster.
Room to re-rate, or risk of de-rating
At 43.0× earnings it costs 1.8× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 37.3×, the 81st percentile of its own range.
Whether growth justifies the valuation
Priced at 5.4 times its growth rate, on earnings growth of 8%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Gland Pharma Limited — this one | 8%/yr | 43.0× | ₹5.4 |
| Sun Pharmaceutical | 13%/yr | 33.4× | ₹2.6 |
| Divi's Laboratories | 13%/yr | 83.3× | ₹6.4 |
| Torrent Pharmaceuticals | 22%/yr | 78.7× | ₹3.6 |
| Zydus Lifesciences | 32%/yr | 23.1× | ₹0.72 |
| Laurus Labs Limited | 4%/yr | 98.6× | ₹24.7 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Pharmaceuticals), it ranks 61 of 130 on returns, 52 of 127 on growth, 40 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
A narrow advantage: it earns 15.1% on capital, ahead of 53% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Yes — Over the last five years it made ₹4098 crore of cash from the business, spent ₹2030 crore on plant and equipment, and returned ₹1599 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 7 years, about 86 arrived as cash. Its cash comes back faster than it used to: it went from being waiting 168 days for its cash to waiting 145 days for its cash.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
7 of 9 checks clear · 78%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Revenue rose 19.5% year over year and net profit rose 47.4%.
Announced 10 Aug 2026 · Consolidated · Unaudited
Revenue
₹1,800 Cr
Revenue vs last year
+19.5%
Revenue vs last quarter
+3.3%
Net profit
₹317 Cr
Profit vs last year
+47.4%
Profit vs last quarter
-13.6%
Net margin
17.6%
EPS
₹19.23
Earnings call transcript · 17 Aug 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹49,266 Cr
- Prev close
- ₹3,079.10
- 52w High
- ₹3,171
- 52w Low
- ₹1,574
- Enterprise value
- ₹47,727 Cr
- Beta
- 0.7
- Price CAGR 1y
- 61.0%
- Price CAGR 3y
- 25.0%
- Price CAGR 5y
- -4.0%
- Price CAGR 10y
- —
Ratios
- Return on assets
- 8.2%
- PEG ratio
- 5.5
- P/E ratio
- 43.0
- P/B ratio
- 4.9
- EV / EBITDA
- 31.3
- Industry P/E
- 38.0
- ROCE
- 15.1%
- ROCE 5y average
- 16.2%
- ROE
- 10.7%
- Debt / Equity
- 0.0
- Interest coverage
- 45.4
- Dividend yield
- 0.6%
- ROE 3y average
- 9.0%
- ROE last year
- 11.0%
Annual P&L
- Annual revenue
- ₹6,431 Cr
- Annual profit
- ₹1,027 Cr
- Operating margin
- 25.0%
- Net profit margin
- 16.0%
- EBITDA margin
- 25.3%
- Sales growth 3y
- 21.1%
- Sales growth 5y
- 13.2%
- Profit growth 3y
- 8.0%
- Profit growth 5y
- 1.0%
- EPS
- ₹62.4
- Sales growth TTM
- 18.0%
- Profit growth TTM
- 49.0%
- Dividend payout
- 32.0%
Quarter P&L
- Sales latest quarter
- ₹1,800 Cr
- Profit latest quarter
- ₹317 Cr
- YoY quarterly sales growth
- 19.6%
- YoY quarterly profit growth
- 47.4%
- OPM latest quarter
- 27.2%
Balance Sheet
- Book Value
- ₹647
- Face Value
- ₹1.0
- Total debt
- ₹284 Cr
- Total cash
- ₹3,359 Cr
- Borrowings
- ₹284 Cr
- Reserves / Equity
- 646.3
Cash Flow
- Operating cash flow
- ₹1,031 Cr
- Free cash flow
- ₹538 Cr
- FCF yield
- 1.0%
- Net cash flow
- ₹803 Cr
Shareholding
- Promoter holding
- 51.8%
- FII holding
- 8.7%
- DII holding
- 30.4%
- Public holding
- 9.1%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | 1,781.00 | 33.8 | 4,27,322 | 0.90 | 2,901.2 | 6.0 | 15,299.9 | 10.5 | 20.5 |
| Divi's Lab. | 9,588.00 | 85.4 | 2,54,531 | 0.31 | 902.0 | 65.5 | 3,080.0 | 27.8 | 22.0 |
| Torrent Pharma. | 4,716.20 | 80.4 | 1,79,389 | 0.81 | 566.0 | 5.8 | 4,921.0 | 54.9 | 15.2 |
| Zydus Lifesci. | 1,153.00 | 23.6 | 1,15,012 | 0.09 | 990.2 | -35.1 | 8,017.0 | 22.0 | 21.1 |
| Laurus Labs | 2,052.80 | 101.4 | 1,10,915 | 0.10 | 362.1 | 125.5 | 2,026.3 | 29.1 | 17.8 |
| Cipla | 1,327.20 | 30.0 | 1,07,221 | 0.98 | 785.6 | -39.2 | 7,119.3 | 2.3 | 15.5 |
| Mankind Pharma | 2,500.00 | 48.4 | 1,03,261 | 0.04 | 574.1 | 29.6 | 4,030.6 | 12.9 | 13.5 |
| Gland Pharma | 3,150.60 | 45.4 | 51,988 | 0.63 | 317.0 | 47.1 | 1,800.3 | 19.6 | 15.1 |
| Median | 417.90 | 34.5 | 2,208 | 0.07 | 13.5 | 29.5 | 164.0 | 18.4 | 15.0 |
Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,209 | 1,373 | 1,545 | 1,537 | 1,402 | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 | 1,800 |
| Expenses | 915 | 1,049 | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 | 1,077 | 1,138 | 1,173 | 1,260 | 1,230 | 1,311 |
| Material Cost | 588 | 557 | 558 | 530 | 594 | 588 | |||||||
| Change in Inventories | -103 | -37 | -6.56 | 45 | -5.02 | 34 | |||||||
| Purchases of Stock-in-Trade | 3.10 | 0.88 | 1.94 | 1.50 | 2.28 | 1.95 | |||||||
| Employee Cost | 373 | 408 | 385 | 424 | 412 | 444 | |||||||
| Other Expenses | 216 | 209 | 234 | 260 | 227 | 243 | |||||||
| Operating Profit | 294 | 324 | 356 | 359 | 264 | 297 | 360 | 348 | 368 | 314 | 435 | 513 | 489 |
| OPM % | 24 | 24 | 23 | 23 | 19 | 21 | 26 | 24 | 24 | 21 | 26 | 29 | 27 |
| Other Income | 38 | 53 | 37 | 42 | 51 | 60 | 58 | 44 | 58 | 84 | 39 | 111 | 61 |
| Exceptional items (within Other Income) | 0 | 0 | 0 | -24 | 0 | 0 | |||||||
| Interest | 5 | 6 | 5 | 10 | 6 | 6 | 23 | 7 | 12 | 8 | 4 | 10 | 4 |
| Depreciation | 65 | 81 | 105 | 93 | 92 | 94 | 96 | 96 | 101 | 106 | 108 | 109 | 111 |
| Profit before tax | 261 | 290 | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 | 362 | 506 | 435 |
| Tax % | 26 | 33 | 32 | 35 | 34 | 36 | 32 | 35 | 31 | 35 | 28 | 28 | 27 |
| Net Profit | 194 | 194 | 192 | 192 | 144 | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 |
| EPS in Rs | 12 | 12 | 12 | 12 | 8.73 | 9.93 | 12 | 11 | 13 | 11 | 16 | 22 | 19 |
| Diluted EPS in Rs | 11 | 13 | 11 | 16 | 22 | 19 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,633 | 3,463 | 4,401 | 3,625 | 5,665 | 5,617 | 6,431 | 6,725 |
| Expenses | 1,678 | 2,161 | 2,890 | 2,600 | 4,332 | 4,348 | 4,801 | 4,974 |
| Material Cost | 1,972 | 2,240 | ||||||
| Change in Inventories | 103 | -3.42 | ||||||
| Purchases of Stock-in-Trade | 14 | 6.60 | ||||||
| Employee Cost | 1,402 | 1,629 | ||||||
| Other Expenses | 856 | 929 | ||||||
| Operating Profit | 955 | 1,302 | 1,510 | 1,025 | 1,333 | 1,269 | 1,630 | 1,751 |
| OPM % | 36 | 38 | 34 | 28 | 24 | 23 | 25 | 26 |
| Other Income | 139 | 135 | 224 | 184 | 170 | 214 | 292 | 296 |
| Exceptional items (within Other Income) | 0 | -24 | ||||||
| Interest | 7 | 3 | 5 | 7 | 26 | 42 | 33 | 26 |
| Depreciation | 95 | 99 | 110 | 147 | 345 | 378 | 424 | 434 |
| Profit before tax | 993 | 1,335 | 1,619 | 1,055 | 1,133 | 1,063 | 1,465 | 1,587 |
| Tax % | 22 | 25 | 25 | 26 | 32 | 34 | 30 | |
| Net Profit | 773 | 997 | 1,212 | 781 | 772 | 699 | 1,027 | 1,129 |
| EPS in Rs | 50 | 61 | 74 | 47 | 47 | 42 | 62 | 68 |
| Diluted EPS in Rs | 42 | 62 | ||||||
| Dividend Payout % | 0 | 0 | 0 | 0 | 43 | 42 | 32 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- 13%
- 3 years
- 21%
- TTM
- 18%
Compounded profit growth
- 10 years
- —
- 5 years
- 1%
- 3 years
- 8%
- TTM
- 49%
Stock price CAGR
- 10 years
- —
- 5 years
- -4%
- 3 years
- 25%
- 1 year
- 61%
Return on equity
- 10 years
- —
- 5 years
- 11%
- 3 years
- 9%
- Last year
- 11%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 3,631 | 5,887 | 7,141 | 7,942 | 8,707 | 9,134 | 10,341 |
| Borrowings | 5 | 5 | 5 | 4 | 372 | 314 | 284 |
| Other Liabilities | 435 | 588 | 671 | 814 | 1,515 | 1,708 | 1,807 |
| Minority Interest | 0 | 0 | |||||
| Total Liabilities | 4,086 | 6,496 | 7,834 | 8,778 | 10,611 | 11,173 | 12,449 |
| Fixed Assets | 968 | 954 | 1,502 | 1,571 | 3,947 | 4,147 | 4,492 |
| CWIP | 188 | 338 | 191 | 177 | 238 | 151 | 342 |
| Investments | 0 | 0 | 155 | 0 | 0 | 0 | 0 |
| Other Assets | 2,929 | 5,204 | 5,986 | 7,030 | 6,426 | 6,875 | 7,614 |
| Total Assets | 4,086 | 6,496 | 7,834 | 8,778 | 10,611 | 11,225 | 12,511 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 701 | 605 | 791 | 364 | 997 | 915 | 1,031 |
| Cash from Investing Activity | -761 | -1,520 | -999 | 1,211 | -1,749 | 1,718 | 188 |
| Cash from Financing Activity | -7 | 1,238 | 35 | 15 | -799 | -433 | -417 |
| Net Cash Flow | -67 | 323 | -174 | 1,590 | -1,552 | 2,199 | 803 |
| Free Cash Flow | 530 | 377 | 269 | 141 | 599 | 521 | 538 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 71 | 99 | 88 | 100 | 99 | 107 |
| Inventory Days | 250 | 312 | 205 | 421 | 278 | 294 | 284 |
| Days Payable | 82 | 97 | 80 | 127 | 129 | 143 | 136 |
| Cash Conversion Cycle | 251 | 286 | 225 | 382 | 250 | 250 | 255 |
| Working Capital Days | 161 | 169 | 168 | 242 | 155 | 173 | 145 |
| ROCE % | 28 | 25 | 15 | 14 | 12 | 15 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
FY revenue / permanent employees + workers, same basis (calc)
1,05,08,061inr
2026-03-31
News
News and filings about Gland Pharma Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- APIs, excipients and pharmaceutical packaging materials
- ertapenem API / penem raw material
- heparin API / crude heparin (porcine-derived)
Buys from
- Beardsell Limited · clean-room / cold-room modular panels — List of Customers logo wall (Gland-Pharma-Limited.…
Sells to
- Breckenridge Pharmaceutical · 7 injectable products marketed/distributed under Breckenridge label in USA
- Dr Reddy's Laboratories · portfolio of 8 injectable ANDAs for US marketing/distribution; biologics CDMO collaboratio…
- Sagent Pharmaceuticals · Heparin Sodium Injection USP (development & supply agreement)
- Sun Pharmaceutical · injectable products / pharmaceutical shipments
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Classification
- Healthcare › Pharmaceuticals
- ISIN
- INE068V01023
Plants
- Cenexi Braine-l'Alleud · Braine-l'Alleud, Walloon Brabant, Belgium
- Cenexi Fontenay-sous-Bois · Fontenay-sous-Bois, Île-de-France, France
- Cenexi Herouville-Saint-Clair
- Cenexi Osny · Osny, Île-de-France, France
- Gland API manufacturing units Visakhapatnam
- Gland Biotech drug substance facility Genome Valley
- Gland Dundigal sterile injectable facility
- Gland Oncology Facility SEZ Visakhapatnam
- Gland Pashamylaram sterile injectable facility
- Gland Penems facility
News impact
Big market events that reach Gland Pharma Limited, and how the effect spreads.
11 Sept, 04:38 IST · Market event · low impact
Govt plans central licensing for all sterile drug manufacturing after quality lapses
India will license all sterile-drug plants centrally after quality lapses, raising compliance costs for injectable makers like Gland and Aurobindo.
Who it hits first
- Sterile-injectable makers (Gland, Aurobindo, Lupin, Caplin, Shilpa) face new licensing layer
- Small job-work sterile units face consolidation pressure
- CDSCO capacity becomes the approval bottleneck
Who may gain
- Large compliant players gain share as small units exit
- Testing and validation service firms gain business
Along the supply chain
Downstream
Hospitals pay slightly more for assured-quality injectables.
Upstream
API and vial suppliers see steadier demand from compliant makers.
Where demand moves
Business
Plants undergo central audits; documentation and QA headcount rise; approvals add months to greenfield timelines.
Capital
Money favours large, audit-ready pharma over small sterile job-workers.
How it spreads across sectors
Healthcare
injectable compliance cost rises; consolidation favours leaders
When it plays out
Immediate
Injectable stocks soften on cost headlines.
Medium term
Cleaner industry commands better US/EU pricing power.
Short term
Watch draft rules, timelines and grandfathering clauses.
23 Jul, 04:24 IST · Market event · high impact
Trump proposes up to 200% tariff on imported generic drugs (phased); Indian pharma falls, takes wait-and-watch stance
Who it hits first
- US-facing Indian generic exporters (DRREDDY, AUROPHARMA, LUPIN, ZYDUSLIFE, GLAND) face a long-dated tariff threat with zero near-term cost
- Sentiment hit today; Nifty Pharma -1.3%
Who may gain
- Domestic-focused pharma/hospitals (APOLLOHOSP, MANKIND, ABBOTINDIA) relatively insulated
- US-based generic manufacturers long-term if reshoring occurs
Along the supply chain
Downstream
US pharmacies/PBMs and patients would bear higher generic costs if the tariff ever takes effect, which is the political friction that makes near-term enactment on essential generics unlikely.
Upstream
Indian API/intermediate suppliers to these formulators see no near-term change; a post-2028 US reshoring push could shift some API demand but also open US-site sourcing.
Where demand moves
Business
No near-term demand change (0% tariff for 2 years). If enacted post-2028, US buyers of Indian generics would face higher landed cost, incentivising reshoring or supplier switching; specialty/injectable makers are harder to displace.
Capital
Near-term risk-off rotation within pharma from high-US-generics names toward domestic-facing pharma and hospitals; the muted, recoverable Sept-2025 precedent limits sustained outflows.
How it spreads across sectors
Healthcare
Domestic hospitals/branded pharma relatively insulated, mild defensive bid
Pharma
US-generic exporters sentiment-negative near-term, neutral medium-term given phasing
When it plays out
Immediate
Sentiment-driven dip in US-exposed generic exporters (Nifty Pharma -1.3%); no earnings impact
Medium term
Neutral through 2026-27 (0% tariff); structural risk only from Aug-2028 (100%) / Aug-2029 (200%) if unmodified — 2 years to reshore or requalify supply
Short term
Wait-and-watch; watch for exemptions/clarifications on essential generics and any reshoring announcements
19 May, 04:29 IST · Market event · medium impact
Q4 aggregate: Hindustan Copper +137% PAT, GNFC +88%, GE Vernova T&D nearly doubles, Apollo Micro +5% on strong Q4; IGL -25%, Afcons slips to loss
Who it hits first
- Beats: HINDCOPPER +137%, GNFC +88%, GE Vernova +98%, Apollo Micro 81% rev, Gland Pharma 52w high
- Misses: IGL -25%, Afcons Rs 88 cr loss
- Mixed: Strides Pharma, Tata Steel (covered separately)
Who may gain
- Capital goods, defence, copper, specialty pharma beat the bar
- City gas distribution, construction missed
Along the supply chain
Downstream
Mixed
Upstream
Mixed
Where demand moves
Business
Earnings dispersion shows demand strength in capex/defence; weakness in gas distribution and infra execution
Capital
Rotation favors capital goods, defence, specialty pharma
How it spreads across sectors
Capital Goods
GE Vernova T&D positive
Chemicals
GNFC positive
Construction
Afcons miss negative
Defense
Apollo Micro confirms theme
Healthcare
Gland Pharma positive
Metals & Mining
HINDCOPPER positive
Oil, Gas & Consumable Fuels
IGL negative
codex additions
When it plays out
Immediate
Stock-specific moves
Medium term
Capital goods/defence theme reinforced; gas distribution structural pressure persists
Short term
Analyst upgrades on beats; downgrades on misses
Other sectors it reaches
- {"causal_chain":"GE Vernova T\u0026D beat reinforces grid modernization and transmission capex; higher equipment ordering can flow through to utilities executing renewable evacuation and interstate transmission projects.","direction":"positive","example_tickers":["POWERGRID","NTPC","TATAPOWER"],"magnitude":"medium","notes":"Beneficiaries are indirect and depend on order awards, regulated capex approvals, and execution timelines.","sector":"Power Utilities \u0026 Grid Operators","time_horizon":"1_to_6_months"}
- {"causal_chain":"Capital goods and T\u0026D strength implies stronger demand for transformers, switchgear, cables, conductors and industrial electrification products.","direction":"positive","example_tickers":["KEI","POLYCAB","CGPOWER"],"magnitude":"medium","notes":"Often reacts as a broader capex basket when T\u0026D earnings surprise positively.","sector":"Electrical Equipment \u0026 Cables","time_horizon":"1_to_4_weeks"}
- {"causal_chain":"Capex-theme confirmation can spill into railway electrification, signalling, rolling stock and EPC suppliers, even if Afcons-specific execution weakness tempers pure construction sentiment.","direction":"mixed","example_tickers":["RVNL","IRCON","TITAGARH"],"magnitude":"medium","notes":"Order-backed railway names may benefit, while EPC-heavy names could face scrutiny on margins and execution.","sector":"Railways \u0026 Mobility Infrastructure","time_horizon":"1_to_4_weeks"}
- {"causal_chain":"Stronger capex and defence/capital-goods earnings support credit demand for working capital, project finance and guarantees; Afcons loss raises select asset-quality and execution-risk questions.","direction":"mixed","example_tickers":["SBIN","BANKBARODA","PFC"],"magnitude":"small","notes":"Impact is broad and second-order; lenders benefit from capex momentum but may price higher risk for infra EPC borrowers.","sector":"Banks \u0026 Infrastructure Finance","time_horizon":"1_to_6_months"}
- {"causal_chain":"Capex strength supports industrial construction, transmission projects and public infrastructure demand; infra execution disappointments may delay near-term volume conversion.","direction":"mixed","example_tickers":["ULTRACEMCO","AMBUJACEM","RAMCOCEM"],"magnitude":"small","notes":"More relevant if capex momentum translates into physical project execution rather than only equipment orders.","sector":"Cement \u0026 Building Materials","time_horizon":"1_to_6_months"}
- {"causal_chain":"Higher metals, chemicals, pharma and capital-goods activity increases movement of bulk cargo, project cargo, exports and warehousing demand.","direction":"positive","example_tickers":["ADANIPORTS","CONCOR","TCI"],"magnitude":"small","notes":"Ripple is demand-linked and may lag reported earnings by one or two quarters.","sector":"Logistics, Ports \u0026 Industrial Warehousing","time_horizon":"1_to_6_months"}
- {"causal_chain":"GNFC strength can improve sentiment toward nitrogen chemicals, fertilizers and agri-input names if margins, gas costs or realization trends look favorable across peers.","direction":"positive","example_tickers":["CHAMBLFERT","RCF","GSFC"],"magnitude":"medium","notes":"GNFC is company-specific, so read-through should be checked against subsidy timing, gas costs and product mix.","sector":"Fertilizers \u0026 Agri Inputs","time_horizon":"1_to_4_weeks"}
- {"causal_chain":"Copper beat and capex strength point to sustained electrification demand across wiring, motors, EV components and industrial automation supply chains.","direction":"positive","example_tickers":["SONACOMS","MOTHERSON","UNOMINDA"],"magnitude":"small","notes":"Transmission from copper/capex to auto ancillaries is indirect but plausible through electrification and component demand.","sector":"Auto Ancillaries \u0026 EV Supply Chain","time_horizon":"1_to_6_months"}
- {"causal_chain":"Gland Pharma strength and 52-week high can spill into injectables, CDMO and complex generics sentiment; GNFC beat may also support chemical margin recovery narratives.","direction":"positive","example_tickers":["LAURUSLABS","DIVISLAB","SYNGENE"],"magnitude":"medium","notes":"Best read-through is to companies with export formulations, CDMO exposure or specialty manufacturing leverage.","sector":"Pharma CDMO \u0026 Specialty Chemicals","time_horizon":"1_to_4_weeks"}
- {"causal_chain":"IGL miss and CGD weakness may indicate pressure from gas pricing, volume softness or margin compression; this can ripple to gas-heavy industrial users and urban consumption proxies.","direction":"mixed","example_tickers":["GUJGA","MGL","KAJARIACER"],"magnitude":"small","notes":"CGD peers may face negative read-through, while downstream gas users could benefit only if input costs soften.","sector":"Consumer Gas-Dependent Industries","time_horizon":"1_to_4_weeks"}
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 11 Aug 2026 | unspecified | ₹20 |
|---|---|---|
| 14 Aug 2025 | unspecified | ₹18 |
| 16 Aug 2024 | unspecified | ₹20 |
Splits, bonuses & buybacks
- daily-prices repair: 7 rows from NSE's archive (replace 2, delete 0, insert 5), 2023-11-12..2026-02-01 (docs/flat_day_repair.md)1× · 12 Nov 2023
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Earnings call · Q1FY2717 Aug 2026
- Earnings call12 Aug 2026
- Annual report · 2025-2631 Jul 2026
- Results presentation30 Jun 2026
- Earnings call · Q4FY2615 May 2026
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.